Literature DB >> 15237132

Composite vascularised osteocutaneous fibula and sural nerve graft for severe open tibial fracture--functional outcome at one year: a case report.

A S Halim1, I Yusof.   

Abstract

Management of severe open tibial fracture with neurovascular injury is difficult and controversial. Primary amputation is an acceptable option as salvaging the injured, insensate, and ischaemic limb may result in chronic osteomyelitis and non-functional limb. We report a case of open tibial fracture associated with segmental bone and soft tissue loss, posterior tibial nerve and artery injuries, which was further complicated by chronic osteo-myelitis treated with composite vascularised osteocutaneous fibula and sural nerve graft. Functional outcome of the injured limb at one-year follow-up was satisfactory: the patient was capable of achieving full weightbearing and was able to appreciate crude touch, pain, proprioception, and temperature at the plantar aspect of the foot. There was no pressure sore or ulceration.

Entities:  

Mesh:

Year:  2004        PMID: 15237132     DOI: 10.1177/230949900401200120

Source DB:  PubMed          Journal:  J Orthop Surg (Hong Kong)        ISSN: 1022-5536            Impact factor:   1.118


  3 in total

Review 1.  Free-Flap Reconstruction of the Mandible.

Authors:  Roderick Y Kim; Mofiyinfolu Sokoya; Yadranko Ducic; Fayette Williams
Journal:  Semin Plast Surg       Date:  2019-03-08       Impact factor: 2.314

2.  Factors associated with the outcome of open tibial fractures.

Authors:  Nazri Mohd Yusof; Kamarul Ariffin Khalid; Ahmad Hafiz Zulkifly; Zamzuri Zakaria; Mohammad Azril Mohammad Amin; Muhammad Shukimi Awang; Aminudin Che Ahmad; Sheikh Farid Uddin Akter
Journal:  Malays J Med Sci       Date:  2013-10

3.  Nerve recovery from treatment with a vascularized nerve graft compared to an autologous non-vascularized nerve graft in animal models: A systematic review and meta-analysis.

Authors:  Berend O Broeren; Liron S Duraku; Caroline A Hundepool; Erik T Walbeehm; J Michiel Zuidam; Carlijn R Hooijmans; Tim De Jong
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.